JP2005514406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514406A5 JP2005514406A5 JP2003557275A JP2003557275A JP2005514406A5 JP 2005514406 A5 JP2005514406 A5 JP 2005514406A5 JP 2003557275 A JP2003557275 A JP 2003557275A JP 2003557275 A JP2003557275 A JP 2003557275A JP 2005514406 A5 JP2005514406 A5 JP 2005514406A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- nitric oxide
- oxide donor
- stem cells
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002840 nitric oxide donor Substances 0.000 claims description 7
- 230000004766 neurogenesis Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 210000000130 stem cell Anatomy 0.000 claims 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000003416 augmentation Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000007658 neurological function Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 5
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34547802P | 2002-01-04 | 2002-01-04 | |
| PCT/US2003/000323 WO2003056899A2 (en) | 2002-01-04 | 2003-01-06 | Nitric oxide donors for treatment of disease and injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009181759A Division JP2009256374A (ja) | 2002-01-04 | 2009-08-04 | 疾患および損傷の処置のための一酸化窒素ドナー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005514406A JP2005514406A (ja) | 2005-05-19 |
| JP2005514406A5 true JP2005514406A5 (enExample) | 2009-09-24 |
| JP4545440B2 JP4545440B2 (ja) | 2010-09-15 |
Family
ID=23355218
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557275A Expired - Fee Related JP4545440B2 (ja) | 2002-01-04 | 2003-01-06 | 疾患および損傷の処置のための一酸化窒素ドナー |
| JP2009181759A Pending JP2009256374A (ja) | 2002-01-04 | 2009-08-04 | 疾患および損傷の処置のための一酸化窒素ドナー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009181759A Pending JP2009256374A (ja) | 2002-01-04 | 2009-08-04 | 疾患および損傷の処置のための一酸化窒素ドナー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050143388A1 (enExample) |
| EP (1) | EP1469852A4 (enExample) |
| JP (2) | JP4545440B2 (enExample) |
| CN (1) | CN1638775A (enExample) |
| AU (1) | AU2003210447B2 (enExample) |
| CA (1) | CA2471147C (enExample) |
| IL (1) | IL162850A0 (enExample) |
| WO (1) | WO2003056899A2 (enExample) |
| ZA (1) | ZA200405507B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007010337A2 (de) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben |
| US20090246145A1 (en) * | 2005-11-14 | 2009-10-01 | Small Scott A | Imaging Correlates of Neurogenesis With MRI |
| US8841300B2 (en) | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| CN101754756A (zh) * | 2007-05-18 | 2010-06-23 | 维瓦斯公司 | 包含磷酸二酯酶-5抑制剂的新组合和它们的用途 |
| WO2009046377A2 (en) * | 2007-10-04 | 2009-04-09 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
| US20100316622A1 (en) * | 2007-11-02 | 2010-12-16 | University Of Miami | Diagnosis and treatment of cardiac disorders |
| SG11201406552UA (en) | 2012-04-25 | 2014-11-27 | Takeda Pharmaceutical | Nitrogenated heterocyclic compound |
| US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
| ES2635016T3 (es) * | 2013-03-01 | 2017-10-02 | Fundación Para La Investigación Médica Aplicada | Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas |
| JP6280912B2 (ja) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| US10297661B2 (en) * | 2017-06-30 | 2019-05-21 | Taiwan Semiconductor Manufacturing Co., Ltd. | High voltage resistor device |
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI964113A7 (fi) * | 1994-04-15 | 1996-10-14 | Iyo Masaomi | Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö |
| US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| US6043223A (en) * | 1997-11-12 | 2000-03-28 | The Regents Of The University Of California | Enhanced opening of abnormal brain tissue capillaries |
| DE19834507A1 (de) * | 1998-07-31 | 2000-02-03 | Hexal Ag | Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil |
| CA2373808C (en) * | 1999-05-14 | 2011-04-19 | Henry Ford Health System | Bone marrow transplantation for treatment of central nervous system damage |
| JP2003532622A (ja) * | 1999-06-14 | 2003-11-05 | ヘンリー フォード ヘルス システム | 神経発生を誘導する一酸化窒素ドナー |
| US6075028A (en) * | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
| IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| US6271228B1 (en) | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
| ES2373540T3 (es) * | 2000-08-10 | 2012-02-06 | Cold Spring Harbor Laboratory | Entrenamiento cognitivo aumentado. |
-
2003
- 2003-01-06 CN CNA038048817A patent/CN1638775A/zh active Pending
- 2003-01-06 US US10/500,694 patent/US20050143388A1/en not_active Abandoned
- 2003-01-06 CA CA2471147A patent/CA2471147C/en not_active Expired - Fee Related
- 2003-01-06 IL IL16285003A patent/IL162850A0/xx unknown
- 2003-01-06 AU AU2003210447A patent/AU2003210447B2/en not_active Ceased
- 2003-01-06 JP JP2003557275A patent/JP4545440B2/ja not_active Expired - Fee Related
- 2003-01-06 EP EP03729347A patent/EP1469852A4/en not_active Withdrawn
- 2003-01-06 WO PCT/US2003/000323 patent/WO2003056899A2/en not_active Ceased
-
2004
- 2004-07-12 ZA ZA2004/05507A patent/ZA200405507B/en unknown
-
2009
- 2009-08-04 JP JP2009181759A patent/JP2009256374A/ja active Pending
-
2010
- 2010-09-24 US US12/889,873 patent/US20120009152A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514406A5 (enExample) | ||
| Shen et al. | Stem cell‐derived extracellular vesicles attenuate the early inflammatory response after tendon injury and repair | |
| Chio et al. | Microglial activation as a compelling target for treating acute traumatic brain injury | |
| Horie et al. | Enhancement of satellite cell differentiation and functional recovery in injured skeletal muscle by hyperbaric oxygen treatment | |
| Zheng et al. | Stroke recovery and rehabilitation in 2016: a year in review of basic science and clinical science | |
| Li et al. | Advances in the treatment of ischemic diseases by mesenchymal stem cells | |
| Colombo et al. | Modeling hypoxia induced factors to treat pulpal inflammation and drive regeneration | |
| JP2019142831A5 (enExample) | ||
| Wang et al. | Valproic acid labeled chitosan nanoparticles promote the proliferation and differentiation of neural stem cells after spinal cord injury | |
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| EP2330111A3 (en) | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases | |
| CN107137700B (zh) | 一种基于干细胞源外泌体的组合物及其在制备治疗心肌梗死的药物中的应用 | |
| Shirzad et al. | Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine | |
| García-Ayuso et al. | Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations | |
| Tan et al. | Biomaterial‐Facilitated Local Delivery of Stem Cell‐Derived Small Extracellular Vesicles: Perspectives in Surgical Therapy | |
| Li et al. | Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury | |
| Gelmetti et al. | Innovative therapeutics in pediatric dermatology | |
| CN113521309B (zh) | 人肝细胞生长因子基因在湿疹治疗中的应用及微针药械 | |
| JP2022526820A (ja) | 間葉系幹細胞およびそのエクソソームによる微小血管障害の治療 | |
| JP5334584B2 (ja) | アミノ酸とヒアルロン酸ナトリウムを基にした滅菌粉末の形態の創傷治癒医薬組成物 | |
| Ara et al. | Effect of various treatment modalities after spinal cord injury | |
| Fu et al. | New hope for esophageal stricture prevention: A prospective single-center trial on acellular dermal matrix | |
| CN1258371C (zh) | 包括大根草有机提取物的组合物及其应用 | |
| CN111920827B (zh) | 促组织愈合的复方缓释纳米粒的制备方法 | |
| Soria et al. | Treatment of pyoderma gangrenosum with cyclosporin A |